Imdevimab
As of the edition of 20 October 2026, Imdevimab is an antibody: marketed, first approved in 2021 (JP).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2021
- Kind
- Antibody
- First approved
- 19 July 2021 (JP)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Roche
- Withdrawn from market
- 5 December 2025 (in some regions)
- Registered trials
- 13, 5 stopped early
- Disease areas
- Infections; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 2 | 1 | 0 |
| Phase 1 | 3 | 2 | 0 | 1 |
| Phase 2 | 4 | 1 | 0 | 2 |
| Phase 3 | 2 | 1 | 0 | 1 |
| Phase 4 | 1 | 0 | 0 | 1 |
| All trials | 13 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Roche | Originator | 2021 to now |